ELISA methodology for detection of modified osteoprotegerin in clinical studies.
Chen
D
D
Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA. dchen@amgen.com
Sarikaya
N A
NA
Gunn
H
H
Martin
S W
SW
Young
J D
JD
D000818:Animals; D000911:Antibodies, Monoclonal; D002986:Clinical Trials as Topic; D004797:Enzyme-Linked Immunosorbent Assay; D006023:Glycoproteins / Q000097:blood* / Q000276:immunology; D006801:Humans; D051379:Mice; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood* / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood* / Q000276:immunology
D000911:Antibodies, Monoclonal; D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; C506031:Tnfrsf11b protein, mouse